BR9712248A - Antagonista receptores de vitronectina - Google Patents
Antagonista receptores de vitronectinaInfo
- Publication number
- BR9712248A BR9712248A BR9712248A BR9712248A BR9712248A BR 9712248 A BR9712248 A BR 9712248A BR 9712248 A BR9712248 A BR 9712248A BR 9712248 A BR9712248 A BR 9712248A BR 9712248 A BR9712248 A BR 9712248A
- Authority
- BR
- Brazil
- Prior art keywords
- receptor antagonist
- vitronectin receptor
- vitronectin
- antagonist
- receptor
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D223/16—Benzazepines; Hydrogenated benzazepines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/582—Recycling of unreacted starting or intermediate materials
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Inorganic Chemistry (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US2732096P | 1996-10-02 | 1996-10-02 | |
| US4377697P | 1997-04-11 | 1997-04-11 | |
| PCT/US1997/018001 WO1998014192A1 (en) | 1996-10-02 | 1997-10-01 | Vitronectin receptor antagonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR9712248A true BR9712248A (pt) | 1999-08-24 |
| BR9712248B1 BR9712248B1 (pt) | 2010-06-29 |
Family
ID=26702318
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI9712248-3A BR9712248B1 (pt) | 1996-10-02 | 1997-10-01 | antagonistas receptores de vitronectina. |
Country Status (37)
| Country | Link |
|---|---|
| EP (1) | EP0957917B1 (pt) |
| JP (2) | JP4491072B2 (pt) |
| KR (1) | KR100589578B1 (pt) |
| CN (1) | CN1114403C (pt) |
| AP (1) | AP1463A (pt) |
| AR (1) | AR008878A1 (pt) |
| AT (1) | ATE312089T1 (pt) |
| AU (1) | AU733417B2 (pt) |
| BG (1) | BG64581B1 (pt) |
| BR (1) | BR9712248B1 (pt) |
| CA (1) | CA2267224C (pt) |
| CO (1) | CO4900046A1 (pt) |
| CY (1) | CY2576B1 (pt) |
| CZ (1) | CZ299076B6 (pt) |
| DE (1) | DE69734833T2 (pt) |
| DK (1) | DK0957917T3 (pt) |
| DZ (1) | DZ2320A1 (pt) |
| EA (1) | EA002419B1 (pt) |
| ES (1) | ES2252775T3 (pt) |
| HK (1) | HK1023730A1 (pt) |
| HU (1) | HU229221B1 (pt) |
| ID (1) | ID19623A (pt) |
| IL (1) | IL129243A (pt) |
| MA (1) | MA24361A1 (pt) |
| MY (1) | MY137606A (pt) |
| NO (1) | NO320194B1 (pt) |
| NZ (1) | NZ334953A (pt) |
| PE (1) | PE10499A1 (pt) |
| PL (1) | PL190859B1 (pt) |
| RO (1) | RO119881B1 (pt) |
| SA (1) | SA98180936B1 (pt) |
| SK (1) | SK285029B6 (pt) |
| TR (1) | TR199900737T2 (pt) |
| TW (1) | TW487702B (pt) |
| UA (1) | UA60311C2 (pt) |
| UY (2) | UY24735A1 (pt) |
| WO (1) | WO1998014192A1 (pt) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA60311C2 (uk) * | 1996-10-02 | 2003-10-15 | Смітклайн Бічам Корпорейшн | Антагоністи рецептора вітронектину, спосіб одержання цих сполук та фармацевтична композиція |
| TW527355B (en) | 1997-07-02 | 2003-04-11 | Bristol Myers Squibb Co | Inhibitors of farnesyl protein transferase |
| IL135188A0 (en) * | 1997-09-24 | 2001-05-20 | Smithkline Beecham Corp | Vitronectin receptor antagonist |
| TR200000792T2 (tr) * | 1997-09-24 | 2000-09-21 | Smithkline Beecham Corporation | Vitronektin reseptör antagonistleri. |
| US6372719B1 (en) | 1998-03-04 | 2002-04-16 | Jay Cunningham | ανβ3 integrin antagonists in combination with chemotherapeutic agents |
| DE19842415A1 (de) | 1998-09-16 | 2000-03-23 | Merck Patent Gmbh | Pharmazeutische Zubereitung |
| WO2000038730A2 (en) * | 1998-12-23 | 2000-07-06 | G.D. Searle & Co. | Use of a cyclooxygenase-2 inhibitor and one or more antineoplastic agents for combination therapy in neoplasia |
| WO2000046215A1 (en) * | 1999-02-03 | 2000-08-10 | Merck & Co., Inc. | Benzazepine derivatives as alpha-v integrin receptor antagonists |
| DE60007960T2 (de) * | 1999-04-30 | 2004-10-21 | Univ Michigan Ann Arbor | Therapeutische Anwendungen von pro-apoptotischen Benzodiazepinen |
| AU6523200A (en) * | 1999-08-06 | 2001-03-05 | Smithkline Beecham Corporation | Vitronectin receptor antagonists useful for the treatment of strokes |
| US6514964B1 (en) | 1999-09-27 | 2003-02-04 | Amgen Inc. | Fused cycloheptane and fused azacycloheptane compounds and their methods of use |
| DE10028575A1 (de) | 2000-06-14 | 2002-03-14 | Basf Ag | Integrinliganden |
| DE10027514A1 (de) * | 2000-06-06 | 2002-01-03 | Basf Ag | Liganden von Integrinrezeptoren |
| FR2806082B1 (fr) * | 2000-03-07 | 2002-05-17 | Adir | Nouveaux composes bicycliques antagonistes des recepteurs de la vitronectine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| CA2436130A1 (en) | 2001-01-29 | 2002-08-08 | 3-Dimensional Pharmaceuticals, Inc. | Substituted indoles and their use as integrin antagonists |
| OA12505A (en) * | 2001-04-10 | 2006-05-29 | Smithkline Beecham Corp | Method of inhibiting adhesion formation. |
| SE0101386D0 (sv) | 2001-04-20 | 2001-04-20 | Astrazeneca Ab | New compounds |
| WO2002090325A2 (en) * | 2001-05-03 | 2002-11-14 | Merck & Co., Inc. | Benzazepinone alpha v integrin receptor antagonists |
| WO2003059251A2 (en) | 2001-10-22 | 2003-07-24 | The Scripps Research Institute | Antibody targeting compounds |
| GB0215867D0 (en) * | 2002-07-09 | 2002-08-14 | Glaxosmithkline Spa | Novel method and compounds |
| US7368566B2 (en) * | 2003-04-04 | 2008-05-06 | Smithkline Beecham Corporation | Process and intermediates for preparing benzazepines |
| CN1964740A (zh) * | 2004-04-02 | 2007-05-16 | 加利福尼亚大学董事会 | 治疗和预防与αVβ5整联蛋白有关的疾病的方法和组合物 |
| AU2012216372B2 (en) * | 2004-04-02 | 2015-01-22 | The Regents Of The University Of California | Methods and compositions for treating and preventing disease associated with alphaVbeta5 integrin |
| UA87854C2 (en) | 2004-06-07 | 2009-08-25 | Мерк Энд Ко., Инк. | N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators |
| WO2006069079A2 (en) * | 2004-12-21 | 2006-06-29 | Smithkline Beecham Corporation | Methods and formulations |
| WO2007064752A2 (en) * | 2005-11-29 | 2007-06-07 | Smithkline Beecham Corporation | Treatment of ocular neovascular disorders such as macular degeneration, angiod streaks, uveitis and macular edema |
| ES2457822T3 (es) | 2007-11-08 | 2014-04-29 | The General Hospital Corporation | Procedimientos y composiciones de tratamiento de enfermedades proteinúricas |
| AU2008321770B2 (en) * | 2007-11-16 | 2012-09-06 | Ube Industries, Ltd. | Benzazepinone compound |
| US8076475B2 (en) * | 2008-03-06 | 2011-12-13 | Glaxosmithkline Llc | Process |
| WO2010093706A2 (en) | 2009-02-10 | 2010-08-19 | The Scripps Research Institute | Chemically programmed vaccination |
| EP2415474B1 (en) * | 2009-03-30 | 2013-08-28 | Ube Industries, Ltd. | Pharmaceutical composition for treatment or prevention of ophthalmic diseases |
| JP5572996B2 (ja) * | 2009-05-15 | 2014-08-20 | 宇部興産株式会社 | ベンズアゼピノン化合物を有効成分として含有する医薬 |
| BR112012001463A2 (pt) | 2009-07-24 | 2016-03-15 | Univ California | métodos e composições para tratar e prevenir doença associada à integrina alfavbeta5 |
| CA2915237C (en) | 2009-11-17 | 2017-10-10 | The Regents Of The University Of Michigan | 1,4-benzodiazepine-2,5-diones and related compounds with therapeutic properties |
| EP2325194A1 (en) * | 2009-11-24 | 2011-05-25 | Glycotope GmbH | Process for the purification of glycoproteins |
| WO2015181676A1 (en) | 2014-05-30 | 2015-12-03 | Pfizer Inc. | Carbonitrile derivatives as selective androgen receptor modulators |
| AU2021262281A1 (en) * | 2020-04-26 | 2022-11-24 | Jiangsu Nhwa Pharmaceutical Co., Ltd. | 1,5-dihydro-2,4-benzodiazepine-3-one derivative and application thereof |
| WO2023275715A1 (en) | 2021-06-30 | 2023-01-05 | Pfizer Inc. | Metabolites of selective androgen receptor modulators |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1041921C (zh) * | 1992-12-21 | 1999-02-03 | 史密丝克莱恩比彻姆公司 | 双环血纤维蛋白原拮抗剂 |
| JPH10504808A (ja) * | 1994-06-29 | 1998-05-12 | スミスクライン・ビーチャム・コーポレイション | ビトロネクチン受容体拮抗物質 |
| JPH10504807A (ja) * | 1994-06-29 | 1998-05-12 | スミスクライン・ビーチャム・コーポレイション | ビトロネクチン受容体拮抗剤 |
| US6008214A (en) * | 1994-08-22 | 1999-12-28 | Smithkline Beecham Corporation | Bicyclic compounds |
| WO1996026190A1 (en) * | 1995-02-22 | 1996-08-29 | Smithkline Beecham Corporation | Integrin receptor antagonists |
| UA60311C2 (uk) * | 1996-10-02 | 2003-10-15 | Смітклайн Бічам Корпорейшн | Антагоністи рецептора вітронектину, спосіб одержання цих сполук та фармацевтична композиція |
-
1997
- 1997-01-10 UA UA99031739A patent/UA60311C2/uk unknown
- 1997-09-29 DZ DZ970170A patent/DZ2320A1/xx active
- 1997-09-30 MY MYPI97004552A patent/MY137606A/en unknown
- 1997-09-30 MA MA24817A patent/MA24361A1/fr unknown
- 1997-10-01 BR BRPI9712248-3A patent/BR9712248B1/pt not_active IP Right Cessation
- 1997-10-01 WO PCT/US1997/018001 patent/WO1998014192A1/en active IP Right Grant
- 1997-10-01 JP JP51694298A patent/JP4491072B2/ja not_active Expired - Fee Related
- 1997-10-01 CN CN97180168A patent/CN1114403C/zh not_active Expired - Fee Related
- 1997-10-01 SK SK425-99A patent/SK285029B6/sk not_active IP Right Cessation
- 1997-10-01 RO RO99-00353A patent/RO119881B1/ro unknown
- 1997-10-01 HU HU9903769A patent/HU229221B1/hu not_active IP Right Cessation
- 1997-10-01 EA EA199900356A patent/EA002419B1/ru not_active IP Right Cessation
- 1997-10-01 AT AT97909979T patent/ATE312089T1/de active
- 1997-10-01 AP APAP/P/1999/001493A patent/AP1463A/en active
- 1997-10-01 PE PE1997000876A patent/PE10499A1/es not_active Application Discontinuation
- 1997-10-01 CZ CZ0113299A patent/CZ299076B6/cs not_active IP Right Cessation
- 1997-10-01 ID IDP973335A patent/ID19623A/id unknown
- 1997-10-01 EP EP97909979A patent/EP0957917B1/en not_active Expired - Lifetime
- 1997-10-01 CO CO97057225A patent/CO4900046A1/es unknown
- 1997-10-01 TR TR1999/00737T patent/TR199900737T2/xx unknown
- 1997-10-01 UY UY24735A patent/UY24735A1/es not_active IP Right Cessation
- 1997-10-01 PL PL332674A patent/PL190859B1/pl unknown
- 1997-10-01 AU AU47462/97A patent/AU733417B2/en not_active Ceased
- 1997-10-01 ES ES97909979T patent/ES2252775T3/es not_active Expired - Lifetime
- 1997-10-01 DK DK97909979T patent/DK0957917T3/da active
- 1997-10-01 KR KR1019997002811A patent/KR100589578B1/ko not_active IP Right Cessation
- 1997-10-01 IL IL12924397A patent/IL129243A/en not_active IP Right Cessation
- 1997-10-01 CA CA002267224A patent/CA2267224C/en not_active Expired - Fee Related
- 1997-10-01 DE DE69734833T patent/DE69734833T2/de not_active Expired - Lifetime
- 1997-10-01 NZ NZ334953A patent/NZ334953A/xx not_active IP Right Cessation
- 1997-10-02 AR ARP970104549A patent/AR008878A1/es active IP Right Grant
-
1998
- 1998-02-10 TW TW086114545A patent/TW487702B/zh not_active IP Right Cessation
- 1998-03-01 SA SA98180936A patent/SA98180936B1/ar unknown
- 1998-03-25 UY UY24935A patent/UY24935A1/es not_active IP Right Cessation
-
1999
- 1999-03-31 NO NO19991590A patent/NO320194B1/no not_active IP Right Cessation
- 1999-03-31 BG BG103299A patent/BG64581B1/bg unknown
-
2000
- 2000-05-22 HK HK00103033A patent/HK1023730A1/xx not_active IP Right Cessation
-
2007
- 2007-05-18 CY CY0700010A patent/CY2576B1/xx unknown
-
2009
- 2009-10-09 JP JP2009235447A patent/JP2010006838A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR9712248A (pt) | Antagonista receptores de vitronectina | |
| BR9508178A (pt) | Antagonistas de receptor de vitronectina | |
| BR9612327A (pt) | Antagonistas receptores de vitronectina | |
| BR9612378A (pt) | Antagonistas receptores de vitronectina | |
| NO983001D0 (no) | Vitronectin-reseptor-antagonister | |
| NO972016D0 (no) | Indolyl-Y-reseptorantagonister | |
| BR9709952A (pt) | Antagonistas de receptor de il-8 | |
| NO986109D0 (no) | IL-8 reseptor-antagonister | |
| DE69812096D1 (de) | Neuropeptid y rezeptorantagonisten | |
| NO993350D0 (no) | Vitronectin-reseptor-antagonister | |
| EP1000031A4 (en) | VITRONECTIN RECEPTOR ANTAGONISTS | |
| BR9711140A (pt) | Antagonistas receptores de il-8 | |
| NO20001514D0 (no) | Vitronectin-reseptor-antagonist | |
| NO20001515D0 (no) | Vitronektin reseptor-antagonist | |
| ID24726A (id) | Antagonis-antagonis reseptor trombin | |
| NO20004503L (no) | Vitronectin-reseptor-antagonister | |
| NO20001407D0 (no) | Vitronectin-reseptor-antagonister | |
| DK0906294T3 (da) | Benzoxazinon-dopamin D4-receptor-antagonister | |
| BR9507220A (pt) | Antagonistas de receptores de endotelina | |
| DZ2322A1 (fr) | Antagonistes de récepteurs de vitronectine. | |
| PT1146874E (pt) | Antagonista de receptor da vitronectina | |
| BR9609914A (pt) | Antagonista do receptor de endotelina | |
| NO20010620D0 (no) | Vitronektinreseptor-antagonister | |
| DE69830671D1 (de) | Integrin-rezeptor-antagonisten |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 29/06/2010, OBSERVADAS AS CONDICOES LEGAIS. |
|
| B25D | Requested change of name of applicant approved |
Owner name: GLAXOSMITHKLINE LLC (US) Free format text: NOME ALTERADO DE: SMITHKLINE BEECHAM CORPORATION |
|
| B21F | Lapse acc. art. 78, item iv - on non-payment of the annual fees in time |
Free format text: REFERENTE A 14A ANUIDADE. PAGAR RESTAURACAO. |
|
| B21H | Decision of lapse of a patent or of a certificate of addition of invention cancelled [chapter 21.8 patent gazette] |
Free format text: REFERENTE AO DESPACHO 21.6 PUBLICADO NA RPI 2343 DE 01/12/2015. |
|
| B21F | Lapse acc. art. 78, item iv - on non-payment of the annual fees in time | ||
| B24J | Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12) |